Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2023-10-29 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023 Third Quarter Report" of 华兰生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including balance sheets, income statements, and cash flow statements for the third quarter of 2023. The document explicitly states it is a quarterly report and is unaudited. The length of the document (11,588 characters) and the presence of comprehensive financial data confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-10-29 Chinese
关于调整董事会审计委员会成员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the adjustment of members of the company's Board Audit Committee. It details changes in board committee membership and compliance with regulatory requirements. There is no financial data, no report attached or referenced as being published, and no mention of voting results or executive compensation. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-10-29 Chinese
第八届监事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the Supervisory Board of a company regarding the resolution passed in their ninth meeting of the eighth Supervisory Board. It details the approval of a restricted stock grant to incentive recipients, including the number of shares, price, and compliance with relevant laws and company regulations. The document is short (1046 characters) and focuses on the meeting resolution and voting results rather than providing a full report or detailed financial data. It is not an annual report, audit report, or financial statement. It is also not a general regulatory filing or a report publication announcement since it contains substantive content about the board's decision. The content aligns best with Board/Management Information (MANG) as it relates to decisions made by the company's supervisory board regarding management incentives and stock grants.
2023-10-16 Chinese
安徽承义律师事务所关于华兰生物工程股份有限公司2023年限制性股票激励计划首次授予事项的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2023 restricted stock incentive plan's first grant. It contains detailed legal analysis, approvals, authorizations, and compliance with relevant laws and regulations. It is not a financial report, earnings release, or management discussion. It is a standalone legal opinion related to a specific corporate action (stock incentive plan). The document length is 6603 characters, which is substantial and contains detailed content, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR), as it is a legal opinion report related to corporate governance and compliance matters, not a full annual report or other categories. FY 2023
2023-10-16 Chinese
安徽承义律师事务所关于华兰生物工程股份有限公司独立董事公开征集委托投票权的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the independent director's public solicitation of proxy voting rights for a specific shareholders' meeting of a company. It discusses the legal basis, qualifications of the solicitor, procedures, and results of the proxy solicitation related to a 2023 extraordinary general meeting. The document is not a financial report, earnings release, or management discussion. It is a legal proceeding related document providing a formal legal opinion on a corporate governance matter. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 4030 characters, which is relatively short but contains substantive legal content rather than just an announcement or certification, so it is not RNS or RPA.
2023-10-16 Chinese
监事会关于2023年限制性股票激励计划授予日激励对象名单的核查意见
Capital/Financing Update Classification · 95% confidence The document is a formal opinion from the Supervisory Board regarding the verification of the list of incentive recipients for a 2023 restricted stock incentive plan. It discusses the approval of the grant date and the eligibility of the recipients under relevant laws and company regulations. There is no financial report, earnings data, or detailed financial analysis. The document is an announcement related to a capital incentive plan, specifically the granting of restricted stock to certain employees and management. This fits best under Capital/Financing Update (CAP), as it concerns the issuance of shares as part of an incentive plan.
2023-10-16 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.